The Clinical Investigator Collaborative (CIC) is a multi-centre, Canadian-based Phase Ib/IIa clinical trials collaborative that fast-tracks drug candidates for the treatment of asthma and other airways diseases.

CIC conducts proof-of-concept studies that determine pharmacological activity, pharmacokinetics, target engagement, and efficacy of potential new drugs for airways disease using highly reliable clinical models. CIC is unique globally in its ability to undertake early-stage clinical trials to evaluate the efficacy of new molecules and compounds to treat inflammation in the lung, using well validated methods, with proprietary SOPs, while providing for novel opportunities to study the mechanisms of disease.

CIC has ready access to a stable, exquisitely well-phenotyped subject population, and the unique ability to offer its clinical trials service in a multi-institutional setting, with uniform standards and quality assurance across institutions. CIC is active in six institutions across Canada and one in Sweden, and engages various other international partners. The Collaborative has completed 2 to 3 select clinical trials per year since its establishment in 2005.